Chimeric canine anti-CD20 antibody
AssigneeElanco US Inc.
InventorJames David Pancook
Life of this patent
Estimating the term…
Abstract
The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hodgkins B-cell lymphoma in dogs.
Claims10
An antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO:
- 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO:
- 3.
A method of treating lymphoma in a canine patient, comprising administering to a lymphoma cancer canine patient in need of such treatment an effective amount of an antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO:
- 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO:
- 3, wherein the antibody specifically binds to canine CD20.
A kit, comprising a pharmaceutical composition, comprising an antibody which specifically binds to canine CD20, with one or more pharmaceutically acceptable carriers, diluents, or excipients;
- wherein the antibody which specifically binds to canine CD20 comprises a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO:
- 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.